Steinmeyer Law opens investigation into Aimmune Therapeutics, Inc

By: Steinmeyer Law
 
 
Spread the Word
Listed Under

Tags:
Class Action
Securities Litigation

Industry:
Legal

Location:
Columbia - South Carolina - US

Subject:
Deals

COLUMBIA, S.C. - Oct. 27, 2015 - PRLog -- Steinmeyer Law is investigating circumstances involving discrepancies of information pertaining to Aimmune Therapeutics, Inc. (AIMT) on behalf of shareholders, for possible violations of US laws.

On August 6 Aimmune Therapeutics, Inc. (“Aimmune” or the “Company”)  completed an IPO for 160 million.  The Prospectus omitted among other things that COO Raff was already planning his departure, to be revealed less than 2 months later on Oct 6, 2015.   59 days later announces that a COO is retiring, causing the shares to decline as shareholders realized Raff’s pedigree would cause questions about their credibility.

IN THE REGISTRARION STATEMENT AND PROSPECUTS DR “Howard V. Raff, Ph.D., was not only described as the second employee but the COO serving as both key scientific and management as  as he has ” served as our Chief Operating Officer since July 2012. From 2007 to March 2012, Dr. Raff served as Chief Operating Officer for APT Pharmaceuticals, Inc., a pharmaceutical company. Dr. Raff was Vice President of Development Management for Chiron Corporation, a biotechnology company, from 1995 until its acquisition by Novartis International AG, a pharmaceutical company, in 2006. Dr. Raff also served as the head of west coast operations for The Biologics Consulting Group, a regulatory consulting firm in product development and regulatory strategy for biologics, drugs and medical devices, and spent 11 years in discovery research and development for Bristol-Myers Squibb, a pharmaceutical company. Dr. Raff has been involved with the development and approval of several drugs in the U.S. and Europe, including CTLA4-lg, Proleukin, Menjugate vaccine and Cubicin. Dr. Raff received a B.S. in Zoology from the University of Illinois and an M.S. and Ph.D. in Immunology and Microbiology from Washington State University.”

If you purchased securities of Aimmune Therapeutics, Inc. (AIMT) and wish to know your rights go to this page https://steinmeyerlaw.com/aimmune-therapeutics-inc-aimt/  or contact Randall Steinmeyer at (612) 424-3741, or by email, info@steinmeyerlaw.com or visit www.steinmeyerlaw.com
End
Email:***@gmail.com
Tags:Class Action, Securities Litigation
Industry:Legal
Location:Columbia - South Carolina - United States
Subject:Deals
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Vector Informatics Inc PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share